The Albert Einstein College of Medicine Cancer Center (AECC) is an NCI-designated Cancer Center that has been continuously funded since 1971.
Our specific aims are to improve the treatment of cancer and our understanding of its biology by conducting innovative clinical trials with translational components when feasible that offer the potential for broad application. Patients are recruited from four affiliated hospitals that see approximately 4000 new cancer patients each year, with 25 full time faculty members and 20 hematology/oncology fellows supported by 18 research staff. During the last grant cycle, AECC members authored or co-authored 41 manuscripts and 25 abstracts related to ECOG studies, enrolled 332 patients on ECOG/CTSU trials, chaired or co-chaired 23 studies (including two trials [E1199, E2197] that accrued over 8000 patients), initiated or reported four new ECOG trials that were based partly or wholly on AECC pilot studies (E1199, E3198, E3493, E1494), and provided scientific leadership in the breast (J. Sparano), gastrointestinal (L. Augenlicht), leukemia (R. Gallagher), lymphoma (J. Sparano), and thoracic committees (S. Keller, R. Perez-Soler). AECC investigators also secured funding to support translational studies in leukemia, gynecological cancer, and gastrointestinal cancer associated with ECOG studies. Other active clinical research programs include an experimental therapeutics program that recruits approximately 100 patients per year on phase I studies, and participation in a phase II CTEP consortium, providing an environment that fosters drug development that may be taken to ECOG; examples of this include several ECOG studies that include BMS-247550 (E2103, E3800, E2301), which underwent phase I-II development at AECC. The AECC serves an ethnically and economically diverse population of 1.3 million people, with 70 percent of residents being minority and 31 percent living below the poverty level, as reflected by nearly 70 percent minority recruitment on ECOG/CTSU trials. The establishment of a clinical research program in an affiliated municipal hospital and a community oncology program will serve to further enhance minority accrual. The recruitment of an internationally recognized physician-scientist (R. Perez-Soler) as Chairman of Department of Medical Oncology and Associate Cancer Center Director in July 2001 has been accompanied by recruitment of 17 new faculty members that will serve to further strengthen the active core of investigators and enhance the group's contributions to ECOG.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA014958-32
Application #
7060374
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1978-06-01
Project End
2007-04-30
Budget Start
2006-06-28
Budget End
2007-04-30
Support Year
32
Fiscal Year
2006
Total Cost
$151,590
Indirect Cost
Name
Albert Einstein College of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
110521739
City
Bronx
State
NY
Country
United States
Zip Code
10461
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903
Smith, M R; Hong, F; Li, H et al. (2017) Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499. Leukemia 31:517-519
Schneider, Bryan P; Shen, Fei; Jiang, Guanglong et al. (2017) Impact of Genetic Ancestry on Outcomes in ECOG-ACRIN-E5103. JCO Precis Oncol 2017:
Garg, Madhur K; Zhao, Fengmin; Sparano, Joseph A et al. (2017) Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). J Clin Oncol 35:718-726
Sanchez-Martin, Marta; Ambesi-Impiombato, Alberto; Qin, Yue et al. (2017) Synergistic antileukemic therapies in NOTCH1-induced T-ALL. Proc Natl Acad Sci U S A 114:2006-2011
Roberts, Kathryn G; Gu, Zhaohui; Payne-Turner, Debbie et al. (2017) High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. J Clin Oncol 35:394-401
Erbe, Amy K; Wang, Wei; Goldberg, Jacob et al. (2017) FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma. Clin Cancer Res 23:2159-2168
Perez Horta, Zulmarie; Goldberg, Jacob L; Sondel, Paul M (2016) Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy. Immunotherapy 8:1097-117
Haas, Naomi B; Manola, Judith; Uzzo, Robert G et al. (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:2008-16
Wilson, Melissa A; Zhao, Fengmin; Khare, Sanika et al. (2016) Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clin Cancer Res 22:374-82

Showing the most recent 10 out of 146 publications